← All trials
NCT05210634
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 11, 2022
- Primary completion
- May 6, 2022
- Completion date
- May 6, 2022
- First posted
- Jan 27, 2022
- Last posted
- May 13, 2022
- Enrollment
- 21
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Canopy Growth CorporationLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.